For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Tesamorelin: origin, structure and research history

Research Library › GHRH & Ghrelin-Receptor

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) that contains all 44 amino acids of the natural hormone plus a six-carbon hexenoyl group at its N-terminus. It was developed by Theratechnologies of Montreal, Canada, and first approved by the FDA in November 2010 under the brand name Egrifta. As of 22 Oct 2026 it is FDA-approved, as Egrifta WR, for one narrow indication in adults with HIV-associated lipodystrophy.

Key facts

TypeSynthetic 44-amino-acid peptide with an N-terminal hexenoyl group
Derived fromHuman growth hormone-releasing hormone, GHRH(1-44)
First describedGRF analog patent granted 2000 (Brazeau and Gravel, Theratechnologies)
Developed byTheratechnologies Inc., Montreal, Canada
Designed targetGHRH receptors on the anterior pituitary
Regulatory status (Oct 2026)FDA-approved as Egrifta WR for a single HIV-related indication; EU application withdrawn 2012; named on WADA 2026 list (S2)

Who developed it

Tesamorelin was developed by Theratechnologies, a drug company based in Montreal, Canada. An early company patent covering analogs of growth hormone-releasing factor (GRF, another name for GHRH) names Paul Brazeau and Denis Gravel as inventors and was granted in February 2000 [3]. Brazeau was also an author on one of the two 1982 papers that first characterized human GHRH [1].

EMD Serono marketed the drug in the United States after its 2010 approval. Steven Grinspoon served as lead U.S. investigator during the clinical program [4].

What it was designed to target

GHRH is a 44-amino-acid peptide released by the hypothalamus that signals the pituitary gland to release growth hormone. Tesamorelin keeps the full human sequence and adds a short hexenoyl group to the front end of the chain [5]. Natural GHRH is broken down quickly in the bloodstream, and the Theratechnologies patent set out to create analogs that resist this degradation [3].

According to its prescribing information, tesamorelin is designed to bind GHRH receptors on the anterior pituitary, which in turn release the body’s own growth hormone in pulses [5].

Why it was created

The clinical program focused on HIV-associated lipodystrophy, a condition in which some people receiving HIV treatment accumulate visceral fat inside the abdomen. When tesamorelin was approved in 2010, no other therapy had been approved for that condition [4].

Research timeline

  • 1982: Human GHRH is isolated and characterized by two Salk Institute teams [1][2].
  • 2000: Theratechnologies’ GRF analog patent is granted [3].
  • 10 Nov 2010: FDA approves Egrifta, based on two phase 3 trials [6][4].
  • 2012: The European marketing application is withdrawn [7].
  • Mar 2025: FDA approves a new formulation, Egrifta WR [8].
  • Sep 2025: Egrifta WR launches in the U.S., and a Future Pak affiliate completes its acquisition of Theratechnologies [9][10].

Regulatory status as of October 2026

As of 22 Oct 2026, tesamorelin is FDA-approved as Egrifta WR. The label limits the indication to reduction of excess abdominal fat in adults with HIV and lipodystrophy, states that it is not indicated for weight loss, and notes that long-term cardiovascular safety has not been established [5]. It is also approved in Canada.

Europe took a different path. Reviewers at the European Medicines Agency reached a provisional view that the benefits did not outweigh the risks, questioning the clinical relevance of the trial findings and raising elevated IGF-1 levels as a safety concern. The application was withdrawn in 2012 [7].

Tesamorelin is named on the 2026 World Anti-Doping Agency Prohibited List under S2 as a GHRH analog, prohibited at all times [11].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who developed tesamorelin?

Tesamorelin was developed by Theratechnologies of Montreal, Canada. An early company patent on GRF analogs lists Paul Brazeau and Denis Gravel as inventors.

Is tesamorelin FDA approved?

Yes. As of 22 Oct 2026 it is FDA-approved as Egrifta WR, only for excess abdominal fat in adults with HIV and lipodystrophy. The original Egrifta was approved on 10 Nov 2010.

How is tesamorelin different from sermorelin?

Sermorelin copies only the first 29 amino acids of human GHRH. Tesamorelin keeps all 44 amino acids and adds a hexenoyl group at the N-terminus, intended to make it more resistant to breakdown.

Is tesamorelin approved in Europe?

No. The European marketing application was withdrawn in 2012 after EMA reviewers took the provisional view that its benefits did not outweigh its risks.

Sources

  1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982 Nov 5;218(4572):585–587. PMID 6812220. Link
  2. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982 Nov 18;300:276–278. doi:10.1038/300276a0. Link
  3. Brazeau P, Gravel D (Theratechnologies Inc.). GRF analogs with increased biological potency. US Patent 6,020,311, granted 1 Feb 2000. Link
  4. Theratechnologies. FDA approves EGRIFTA (tesamorelin for injection), first and only treatment for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Press release, Montréal, 11 Nov 2010 (reposted by FiercePharma). Link
  5. U.S. FDA. EGRIFTA WR (tesamorelin) prescribing information, 2025 (initial U.S. approval 2010). Link
  6. U.S. FDA, Drugs@FDA. BLA 022505, Egrifta (tesamorelin), Theratechnologies; original approval 10 Nov 2010. Link
  7. European Medicines Agency. Egrifta (tesamorelin): withdrawal of the marketing authorisation application (Ferrer Internacional), Jun 2012; and press release of 26 Jun 2012. Link
  8. Theratechnologies. Theratechnologies receives FDA approval for EGRIFTA WR (tesamorelin F8). Press release, 25 Mar 2025 (SEC Form 6-K, Ex. 99.1). Link
  9. Theratechnologies. Press releases list (EGRIFTA WR availability, 5 Sep 2025; acquisition steps, Jul–Sep 2025). Link
  10. Theratechnologies. Theratechnologies announces completion of acquisition by Future Pak. GlobeNewswire, 25 Sep 2025 (via Barchart). Link
  11. World Anti-Doping Agency. 2026 Prohibited List (S2.2.4 growth hormone releasing factors; S2.3 growth factors). In force 1 Jan 2026. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top